MALT Lymphoma prognosis (MALT-IPI)
Estimate prognosis in MALT lymphoma
The MALT-IPI prognostic index was developed using a database of patients treated in an international randomized trial IELSG-19 (n=401) treated with chlorambucil, rituximab, or both. The index was subsequently validated by merging three independent cohorts of MALT lymphoma patients (including 633 patients).
The score is based on 3 simple clinical parameters that were able to discriminate patient prognosis into 3 risk groups (low, intermediate, and high) predictive for event-free and overall survival. The score was also able to discriminate prognosis for patients with gastric or non-gastric MALT lymphoma.